Disc Medicine Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
ITEM 5. OTHER INFORMATION
The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during thethree months ended September 30, 2024:
| Name and Title | Type of Trading Arrangement | Action Taken(Date of Action) | Duration or End Date | Aggregate Number of Securities to be Sold | Description of Trading Arrangement |
|---|---|---|---|---|---|
| John Quisel, J.D., Ph.D.President, Chief Executive Officer, and Director | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption(July 2, 2024) | End Date(April 15, 2025) | Up to 45,623 | Sale |
| William Savage, M.D., Ph.D.Chief Medical Officer | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption(July 18, 2024) | End Date(December 1, 2024) | Up to 23,341 | Sale |
| Rahul Khara, Pharm.D., J.D.General Counsel and Secretary | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption(September 25, 2024) | End Date(February 28, 2025) | Up to 15,000 | Sale |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.